Christopher M. Adams

Biography

Chris Adams has served as President and CEO of Emmyon since its inception in 2012.  He is also a physician-scientist and a Professor of Medicine and the Fraternal Order of Eagles Diabetes Research Chair at the University of Iowa.  After receiving his MD and PhD degrees from University of Iowa in 1999, Chris moved to the University of Texas Southwestern Medical Center, where he completed an internship and residency in Internal Medicine, a fellowship in Endocrinology and Metabolism, and five years of post-doctoral research training with Nobel laureates Drs. Michael Brown and Joseph Goldstein.  In 2006, Chris was recruited back to the University of Iowa, where he was promoted to an endowed chair in 2017.  His clinical practice focuses on the care of patients with diabetes and other endocrine disorders.  His research has primarily focused on the problem of skeletal muscle atrophy.  He was elected to the American Society for Clinical Investigation in 2013 and serves as a standing member of the Skeletal Muscle Biology and Exercise Physiology study section at the National Institutes of Health.  He is lead inventor on 6 issued patents, 3 allowed patents, and 14 pending patent applications, all exclusively licensed to Emmyon.

Research Interest

 Pharmaceutical